Hybrid Antibody-Peptide Molecule for Autoimmune Dermatitis
Summary
Université Toulouse III – Paul Sabatier has published patent application US20260091122A1 for a hybrid molecule combining an antibody Fc fragment with a peptide targeting autoreactive lymphocytes involved in autoimmune dermatitis. The invention covers the covalent bonding of the Fc portion to the targeting peptide and its therapeutic applications for treating autoimmune skin conditions.
What changed
Université Toulouse III – Paul Sabatier has filed USPTO patent application US20260091122A1 (published April 2, 2026, originally filed September 15, 2023 as application 19111946) for a hybrid molecule comprising an antibody Fc fragment covalently bonded to at least one peptide that binds to autoreactive lymphocytes responsible for autoimmune dermatitis. The CPC classifications include A61K 47/6811, A61K 47/68, A61K 47/6889, A61P 37/04, and C07K 14/78, indicating applications in therapeutic compositions and structural proteins.\n\nPharmaceutical and biotechnology companies researching autoimmune dermatological conditions should review the patent claims for potential licensing opportunities or to assess freedom-to-operate for related therapeutic development programs. The inventors—Guy Serre, Cyril Clavel, and Caroline Carle—have claimed both the hybrid molecule composition and its uses in treating autoimmune dermatitis.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Hybrid Molecule Comprising an Antibody FC Portion and at Least One Peptide Binding to a Self-Reactive Lymphocyte Involved in Autoimmune Dermatitis, and Uses Thereof
Application US20260091122A1 Kind: A1 Apr 02, 2026
Assignee
UNIVERSITE TOULOUSE III – PAUL SABATIER
Inventors
Guy Serre, Cyril Clavel, Caroline Carle
Abstract
The invention relates to a hybrid molecule comprising at least one antibody Fc fragment covalently bonded to at least one peptide bonding to an autoreactive lymphocyte, responsible for autoimmune dermatitis, the uses of such a hybrid molecule, as well as the production method thereof.
CPC Classifications
A61K 47/6811 A61K 47/68 A61K 47/6889 A61P 37/04 C07K 14/78
Filing Date
2023-09-15
Application No.
19111946
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.